ADRB2 and obesity disorder: Consistently, we discovered that the anti-obesity effect of PEGyAMPH is abrogated by selective ADRB2 antagonism (BUT, Figures 7H and 7I), further validating the importance of this pathway for PEGyAMPH’s metabolic effects.